ProCE Banner Activity

Immune Checkpoint Inhibitor Therapy in the Clinical Management of Newly Diagnosed SCLC

Slideset Download
Download this slideset to review the latest data informing optimal use of frontline immune checkpoint inhibition for the treatment of advanced SCLC, including an update on the role of biomarkers.

Released: July 09, 2020

Expiration: July 08, 2021

No longer available for credit.

Share

Faculty

Anna F. Farago

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia